Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Gadeta B.V.

Headquarters: Utrecht, Netherlands
Website: N/A
Year Founded: 2015
Status: Acquired

BioCentury | Nov 16, 2021
Product Development

With trial starts and a takeout, γδ therapies start coming of age 

Company data at SITC and ASH for antibodies and cell therapies directing γδ T cells to kill cancers
BioCentury | Nov 11, 2021
Data Byte

The ɣδ T cell therapy pipeline

At least 11 companies are developing ɣδ T cell therapies for cancer, five of which have a candidate in the clinic
BioCentury | Jun 23, 2021
Emerging Company Profile

CellPoint: bringing autologous CAR Ts to point of care

Emerging Company Profile: CellPoint aims to broaden access to CAR Ts with point-of-care manufacturing platform
BioCentury | Mar 30, 2021
Management Tracks

Li departs LianBio as CEO; plus Xilio, Myriad, OKYO and Intravacc

Bing Li has left Perceptive Advisors-backed cross-border company LianBio as CEO, according to his LinkedIn page. Li’s previous roles include CEO of China Biologic Products Holdings Inc.
BioCentury | Feb 28, 2020
Emerging Company Profile

Lava: better safety for bispecifics with γδ T cell engagement

Lava expects its γδ T cell bispecifics will have same efficacy, better safety than CD3 bispecifics
BioCentury | Dec 4, 2019
Finance

Series B boost for ImCheck's gamma delta T cell therapies

ImCheck’s $53M series B will bring at least one T cell-activating antibody to the clinic, broaden immuno-oncology pipeline
BioCentury | Jul 19, 2019
Product Development

Why GammaDelta would do its Takeda build-to-buy all over again

How GammaDelta's 2017 $100 million option deal with Takeda fueled its multi-pronged pipeline strategy
BioCentury | Jul 20, 2018
Company News

Kite looks to Gadeta for gamma delta T cell tech

BioCentury | Jul 19, 2018
Company News

Kite, Gadeta in gamma delta T cell deal

Items per page:
1 - 10 of 22
Help Center
Username
Request a Demo
Request Training
Ask a Question